Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
THALASSA: Plitidepsin in Post-COVID-19 Condition
NCT06766825Phase 2Completed
- Start
- Feb 2025
- Primary completion
- Sep 2026
- Modality
- Cyclic Peptides, Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in post-COVID-19 condition (PCC) comparing A. Plitidepsin Arm, B. Placebo/Plitidepsin and C. Placebo Arm (3 arms). Primary endpoint: Patient Reported Outcomes Measurement Information System 29. Started Feb 2025; status: completed.
02
Drugs
plitidepsin
03
Conditions
post-COVID-19 condition (PCC)
Beyond the preview
Go deeper on NCT06766825.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06766825.